

Heme oxygenase/carbon monoxide signaling pathways: Regulation and functional significance

Stefan W. Ryter, Leo E. Otterbein, Danielle Morse and Augustine M.K. Choi

Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

Abstract

Carbon monoxide (CO), a gaseous second messenger, arises in biological systems during the oxidative catabolism of heme by the heme oxygenase (HO) enzymes. HO exists as constitutive (HO-2, HO-3) and inducible isoforms (HO-1), the latter which responds to regulation by multiple stress-stimuli. HO-1 confers protection *in vitro* and *in vivo* against oxidative cellular stress. Although the redox active compounds that are generated from HO activity (i.e. iron, biliverdin-IX α , and bilirubin-IX α) potentially modulate oxidative stress resistance, increasing evidence points to cytoprotective roles for CO. Though not reactive, CO regulates vascular processes such as vessel tone, smooth muscle proliferation, and platelet aggregation, and possibly functions as a neurotransmitter. The latter effects of CO depend on the activation of guanylate cyclase activity by direct binding to the heme moiety of the enzyme, stimulating the production of cyclic 3':5'-guanosine monophosphate. CO potentially interacts with other intracellular hemoprotein targets, though little is known about the functional significance of such interactions. Recent progress indicates that CO exerts novel anti-inflammatory and anti-apoptotic effects dependent on the modulation of the p38 mitogen activated protein kinase (MAPK)-signaling pathway. By virtue of these effects, CO confers protection in oxidative lung injury models, and likely plays a role in HO-1 mediated tissue protection. (*Mol Cell Biochem* 234/235: 249–263, 2002)

Key words: antioxidant, carbon monoxide, heme oxygenase, hypoxia, iron, oxidative stress, stress response

Introduction

Carbon monoxide (CO) arises in biological systems principally during heme degradation as the oxidation product of the α -methene bridge of heme, a process catalyzed by the heme oxygenase (HO) enzymes [EC 1:14.99.3, heme, hydrogen donor: oxygen oxidoreductase, (α -methene hydroxylating, decyclizing)] [1, 2]. The inducible form of HO, heme oxygenase-1 (HO-1), confers protection against oxidative stress conditions *in vitro* and *in vivo*, through anti-oxidative, anti-apoptotic and anti-inflammatory actions [3–10]. Although the underlying mechanisms in HO-dependent cytoprotection remain incompletely understood, recent evidence has strongly implicated contributory role(s) for endogenous CO generated from HO activity [6, 11]. Previously regarded as metabolic waste, CO affects vascular function by influencing the

regulation of vessel tone, platelet aggregation, and smooth muscle proliferation [12–16]. Studies of HO-1 localization in the brain have implicated HO-derived CO as a neurotransmitter [17]. These potential effects of CO involve its complexation to the heme moiety of soluble guanylate cyclase (sGC), stimulating the production of guanosine 3',5'-cyclic monophosphate (cGMP), a second messenger molecule [14–18]. As a consequence of heme binding, intracellular CO potentially influences the activity of other cellular hemoproteins such as cytochrome p-450, nitric oxide synthase (NOS), NADPH oxidase, and cytochrome-c oxidase, which are involved in vital processes including drug detoxification, inflammation, respiration, and possibly oxygen sensing [19–22].

Recent studies have discovered a potent anti-inflammatory effect of CO: the inhibition of pro-inflammatory cytokine production following inducing stimuli, dependent on

the modulation of mitogen activated protein kinase (MAPK)-signaling cascades [6, 11]. The effects of CO on MAPK apparently occur independently of sGC activation and cGMP production; however the direct physical target of the CO, in this case, remains unknown.

In addition to CO, redox-active heme metabolites may also participate in cellular defense mechanisms (Fig. 1) [23–24]. HO exerts anti-oxidative functions by converting heme, whose intercellular accumulation may elevate intracellular pro-oxidant status [25], into the bile pigments, biliverdin-IX α , and bilirubin-IX α , which have potent antioxidant properties [26]. The reactive iron released from heme by HO activity may follow detoxification pathways involving either sequestration or extracellular efflux [27–29]. By inactivating iron regulatory protein (IRP) activity, iron stimulates the synthesis of the iron sequestration protein ferritin [30–31], promoting a secondary cellular desensitization to oxidative stress [10, 32].

This review will (I) describe the regulation of HO-1 as an inducible source of endogenous CO, (II) describe evidence that HO-1 acts as a mediator of cellular and tissue protection against oxidative stress, and (III) emphasize recent studies that introduce novel anti-apoptotic and anti-inflammatory properties of HO-derived CO in oxidative lung injury models.

Heme oxygenase isozymes: Properties and significance

Heme oxygenase activity generates equimolar CO, ferrous iron (Fe²⁺), and biliverdin-IX α per mole of heme-b oxidized, in a reaction requiring NADPH: cytochrome p-450 reductase [EC 1.6.2.4] as electron donor [1–2, 33–34]. The reduction of biliverdin-IX α to bilirubin-IX α by NAD(P)H: biliverdin reductase [EC 1:3:1:24] completes heme degradation [1–2, 35]. In addition to HO-1, the inducible form, the HO system consists of two constitutively expressed isozymes (HO-2, and HO-3) which represent the products of distinct genes [36–39]. While the *ho-1* gene responds to induction by a broad spectrum of chemical and physical agents, the *ho-2* and *ho-3* genes do not respond to xenobiotic induction [37]. Thus, HO-1 protein occurs at undetectable levels in most tissues and cell types until a stress condition arises, whereas HO-2 may exist at detectable levels in most tissues in the absence of stress. HO-2 occurs abundantly in the central nervous system and vasculature [37, 40], and responds to regulation by adrenal glucocorticoids in the brain [41–42]. HO-1 and HO-2 differ in primary structure and molecular weight (32 and 36 kD respectively, for the rat isozymes), and in their K_m values (0.24, 0.67 μ M, respectively) and reaction rates toward heme [37–38]. HO-2 contains two high affinity heme-binding sites termed heme regulatory domains (HRD) that are distinct from the catalytic heme-binding site. Accessory heme molecules

bound to HO-2 HRD possibly act as a reservoir for small gas molecules, including NO and CO [43–44]. The significance of HO-3, a homolog of HO-2, remains unclear as it demonstrates poor heme catalytic activity [39]. HO enzymes perform a vital physiological function in the turnover of hemoglobin-heme during the metabolism of senescent erythrocytes in reticuloendothelial tissues, especially the spleen, liver and kidney [45]. HO regulates the intracellular concentration of heme, from the turnover of intracellular hemoproteins and cytochromes, and thus governs the redistribution of heme iron in tissues [45–46].

Regulation of *ho-1* by chemical and physical stress

In 1989 Keyse and Tyrrell, using hybrid-selection cloning techniques, identified the major 32-kDa mammalian stress-protein inducible by hydrogen peroxide, ultraviolet-A (UVA, 320–380 nm) radiation, and sodium *m*-arsenite (NaAsO₂), as identical to the rate limiting enzyme in heme degradation, HO-1 [25, 47]. In addition to oxidants, the induction of the *ho-1* gene also follows cellular exposure to agents such as heme [48], pro-inflammatory cytokines [49–53], bacterial endotoxins [49, 51, 54–58], growth factors [59–60], nitric oxide [61–66] and tumor promoters [67–70]. These agents share the ability to directly or indirectly generate intracellular reactive oxygen species (ROS) and/or modulate intracellular redox equilibrium. HO-1 elevation appears as a general indicator of oxidative stress in cells and tissues [25, 71].

Regulation of HO-1 by oxidative stress exemplified by UVA radiation and H₂O₂: The role of intracellular glutathione and iron status

UVA radiation imposes an oxidative stress in cultured cells by exciting intracellular chromophores to produce ROS [72]. Exposure to either UVA radiation or the oxidant H₂O₂ increased the transcriptional rate of the *ho-1* gene, and the steady-state levels of HO-1 mRNA or protein in human skin fibroblasts [25, 47, 73]. The response to UVA-treatment involved singlet molecular oxygen (¹O₂), since it could be enhanced in deuterium oxide (D₂O), which prolongs ¹O₂ lifetime relative to aqueous media, or inhibited by semi-specific ¹O₂ reactive agents [74]. The expression of HO-1 mRNA and protein also increase following cellular exposure to photosensitizers that produce ¹O₂ and other ROS upon light-activation [74–76].

The induction of HO-1 mRNA by ROS generating systems may be enhanced by the depletion of intracellular reduced glutathione GSH, using the drug D,L-buthionine-(*S,R*)-sulfloximine (BSO) which inhibits γ -glutamyl-cysteinyl-synthetase (γ -GCS), the rate limiting step in GSH biosynthesis [77–78].




Fig. 1. Functional consequences of HO activity. Heme oxygenase degrades heme to biliverdin-IX α , carbon monoxide, and iron. Biliverdin-IX α is converted to bilirubin-IX α by NAD(P)H biliverdin reductase. Both bile pigments have potent *in vitro* antioxidant activity. Redox-active iron released from HO activity may promote oxidative damage. However, by inactivating iron regulatory protein (IRP) activity, iron stimulates the synthesis of ferritin, an iron-sequestration protein and possible cytoprotectant. CO derived from the HO reaction has possible significance in the regulation of vascular and neural functions. The stimulation of cGMP-dependent signal transduction pathways may account for the vasodilatory and anti-proliferative effects. CO has potent anti-inflammatory effects, which depend on downregulation of pro-inflammatory cytokine production mediated by modulation of p38 MAPK. The abbreviations used in this figure include: cGMP = guanosine 3',5'-cyclic monophosphate; CO = carbon monoxide; Fe(II) = ferrous iron; Fe(III) = ferric iron; GTP = guanosine triphosphate; IRP = iron regulatory protein; NOS = nitric oxide synthase; p38 MAPK = p38 mitogen activated protein kinase.

BSO treatment sensitizes human fibroblasts to the cytotoxic effects of UVA and ultraviolet B (UVB, 290–320 nm) radiation, and H₂O₂ treatment [79–80]. BSO treatment alone had moderate to little effect on HO-1 mRNA or protein accumulation in human skin fibroblasts or rodent cell lines, respectively [77, 81–82]. However, BSO treatment in combination with H₂O₂ or UVA, amplified the induction response and lowered the UVA fluence necessary to induce HO-1 mRNA levels in human skin fibroblasts [77]. Supplementation with the GSH precursor *N*-acetyl-L-cysteine (NAC) inhibited HO-1 induction in many systems [53, 57–59, 61–62, 83–87]. The induction of HO-1 by oxidants could be inhibited by iron chelators such as desferrioxamine (DFO) or *o*-phenanthroline, suggesting either a pro-oxidative or regulatory role for intracellular chelatable iron [88]. Iron chelators also attenuate HO-1 induction under hyperoxia [89], or hypoxia [86, 90]. Iron may aggravate ROS production and sensitize cells under oxidative stress conditions by acting as a catalyst in membrane lipid peroxidation and Fenton-type reactions [91–92]. Iron may also have more direct roles in the transcriptional and post-transcriptional regulation of gene expression. For example, iron chelation upregulates the DNA binding activity of the hypoxia-inducible factor (HIF1) [93], whereas iron complexation controls the activity of the iron regulatory protein-1, a translational regulator of proteins involved in iron metabolism [31, 94].

Induction of HO-1 by thiol reactive substances: Role of GSH complexation

HO-1 activation responds to numerous thiol (–SH)-reactive compounds that form complexes with intracellular reduced glutathione (GSH), including sodium *m*-arsenite (NaAsO₂), diethylmaleate (DEM), and heavy metal salts [25, 81, 95]. NaAsO₂ reacts with free –SH groups of GSH, and protein, exerting lethal effects by inactivating –SH dependent enzyme functions. *In vivo*, NaAsO₂ by injection increases rat hepatic and renal HO activity [96]. NaAsO₂ and related arsenicals increase HO-1 (32–34-kDa) protein synthesis and mRNA steady state levels as a general response in many cell types [69, 71, 82, 87, 97–101].

Other thiol reactive substances that induce HO-1 include chemicals which conjugate GSH in glutathione *S*-transferase (GST) catalyzed reactions (i.e. diethylmaleate, DEM) to form mixed disulfides (GSSR), many which undergo prior biotransformation to electrophilic intermediates by cytochrome p450/p448 enzymes (i.e. halogenated hydrocarbons) [37]. The complexation and subsequent depletion of GSH by DEM to a degree exceeding 80% induced HO-1 in various cell types [81–82, 102–103]. Sulphydryl oxidants such as diamide, which promote the formation of GSSG are typically ineffective at inducing HO-1 in cell culture [81–82]. While GSSG may be regenerated to GSH by NADPH:glutathione reduct-

ase, GSSR species may not undergo enzymatic reduction, but are detoxified as *N*-acetyl-cysteine (mercapturic acid) derivatives. The –SH reactive substance *N*-ethylmaleimide has little effect on HO-1 induction, due to its preferential reactivity for protein –SH groups rather than GSH [103].

Metal salts (i.e. CdCl₂, CoCl₂, NiCl₂, SiCl₂, HgCl₂ etc.) potentially activate HO-1 *in vivo* [37, 95, 104], as well as in many cell types [25, 48, 68, 81–82, 97, 99–101, 105]. Heavy metals form complexes with thiol groups including cysteine and GSH. When injected into rats, heavy metals depress hepatic GSH levels, which in turn rebound to elevated levels in a compensatory response. Metal-dependent induction of hepatic HO activity may be inhibited by the prior complexation of the metals with thiol compounds, and potentiated by GSH depletion [95]. Transgenic mice lacking the metallothionein –I and –II genes, which code for low molecular weight thiol-rich proteins involved in metal detoxification, display more pronounced hepatic and renal HO-1 mRNA and protein expression following CdCl₂ injection, than wild-type mice [107]. The induction of HO-1 expression by metals is regulated at the transcriptional level, demonstrated *in vitro* and *in vivo* using nuclear run-on analysis [48, 106, 108–109]. Certain metals (i.e. Fe²⁺, Co²⁺, Cu²⁺) undergo ferrochelatase-dependent incorporation into protoporphyrin IX (PPIX) to form metalloporphyrins [104, 109]. Non-heme synthetic metalloporphyrins (i.e. SnPPIX, ZnPPIX) paradoxically inhibit HO enzyme activity but stimulate HO-1 transcription [104, 106, 110–111].

Regulation of HO-1 expression by nitric oxide

The free radical gas nitric oxide (NO) mediates a number of physiological functions, including vasoregulation, neurotransmission, and inflammation. NO serves as a cytotoxic effector species of the macrophage respiratory burst. At high concentrations, NO may exert a ‘nitrosative’ cellular stress, reacting with thiols (including GSH) to form *S*-nitrosothiols, and with O₂[–], to form the pro-oxidant peroxynitrite (ONOO[–]) [112]. Exogenous NO gas administered to human embryonic lung fibroblasts potentially induced HO-1 protein and mRNA levels in a concentration and time-dependent manner [66]. NO donor compounds such as sodium nitroprusside (SNP), *S*-nitroso-*N*-acetylpenicillamine (SNAP), 3-morpholininosydnonimine (SIN-1), and spermine NONOate (SNN) dose and time dependently increased HO expression in various cell culture systems [61–65, 113–114]. The activation of HO-1 by NO donors or NO gas is independent of cGMP production, since cGMP analogues had no effect and involves transcriptional regulation of the *ho-1* gene [62–63, 65–66]. In human fibroblasts, however, NO donors or NO gas stabilized HO-1 mRNA in a NO concentration-dependent fashion [66, 115]. Furthermore, NO donation by SNAP increased detectable non-heme iron levels

in PAEC and stimulated the synthesis of ferritin in a HO-activity dependent manner [64]. The NO metabolite peroxynitrite (ONOO⁻) induced HO-1 in endothelial cells, which could be inhibited by the antioxidants NAC or uric acid [116].

Regulation of HO-1 by pro-inflammatory states

HO-1 elevation may occur as a consequence of inflammation, infection, sepsis and other pathophysiological conditions associated with increased ROS production and may play a protective role in these contexts [51, 58, 117–118]. HO-1 elevation appears as a component of the hepatic acute phase response in humans, and rodents. The lipopolysaccharide (LPS) component of bacterial endotoxin induces HO activity in rat peritoneal macrophages, and in hepatic parenchyma and sinusoidal cells following intraperitoneal injection [56]. In mice, injection of LPS, or the pro-inflammatory cytokines interleukin-1 (IL-1), tumor necrosis factor- α , (TNF α), and interleukin-6 (IL-6) induced hepatic HO-1 mRNA, with the response to IL-1 verified as a transcriptional regulation [51]. The induction of hepatic HO-1 mRNA levels by LPS could be enhanced by GSH depletion and diminished by NAC, suggesting an influence of cellular redox status in the induction mechanism [58]. Likewise, HO-1 expression responded *in vitro* to cellular stimulation with LPS [54], or pro-inflammatory cytokines (IL-1, IL-6, TNF α) [51–53, 119]. In HUVEC, the TNF α mediated induction of HO-1 required protein kinase-C and phospholipase A2, and responded to inhibition by NAC, and intracellular calcium chelation [53]. Interestingly, HO-1 induction (in HUVEC) also responded to treatment with the thrombopoietic cytokine interleukin-11 [119]. Growth factors that mimic cytokine responses with respect to HO-1 induction include transforming growth factor- β (TGF- β), which induced HO-1 protein in human retinal pigment epithelial cells [60], and platelet derived growth factor (PDGF), which stimulated HO-1 mRNA in VSMC [59]. Like the cytokine-mediated responses, the growth factor responses occurred in association with increased intracellular ROS production, and responded to inhibition by NAC treatment.

Regulation of HO-1 by oxygen tension

HO-1 expression responds to fluctuations in the ‘normal’ or acclimated oxygen (O₂) tension of the system [120–122, 86]. Hypoxia, or lowered pO₂, may occur in the cardiovascular system as a consequence of restricted oxygen intake, ischemia, or disease states such as atherosclerosis. Acute hypoxia dilates the systemic vasculature, whereas chronic hypoxia may constrict the pulmonary vasculature, leading to pulmonary hypertension [123–124].

The exposure of mammalian cells to hypoxia *in vitro* trig-

gers cell type-specific alterations in protein expression patterns [125–128]. Following the original observation by Murphy *et al.* that described HO-1 as the major hypoxia-inducible protein in CHO cells [122], the response has also been demonstrated in vascular systems. For example, acute hypoxia induced HO-1 mRNA accumulation in rat organs, including lung, liver, heart, and aorta [121]. Chronic hypoxia induced HO-1 mRNA in both ventricles of the rat heart [129].

In bovine aortic endothelial cells (BAEC), hypoxia treatment induces HO-1 protein levels and HO enzymatic activity, which persisted during subsequent reoxygenation [86]. This response could be abolished by inclusion of iron chelators or NAC in the hypoxic phase, and conversely increased by prior iron loading [86]. Inhibitors of iNOS or NO scavengers, inhibited the induction of HO activity by hypoxia, while treatment with *S*-nitrosoglutathione augmented the response [130]. These reports, taken together, suggest a critical role for iron and intracellular redox equilibrium in the hypoxic activation of HO-1 gene expression.

Hypoxia induced *ho-1* transcription and HO-1 mRNA accumulation in rat aortic vascular smooth muscle cells (VSMC) [14, 121], and pulmonary artery endothelial cells (PAEC) [131]. In PAEC the response occurred in association with increased AP-1 DNA binding activity, whereas in VSMC, involved activation of HIF-1 DNA binding activity [121, 131]. In contrast to wild-type cells, mutant Hepa cell lines deficient in HIF-1 β did not exhibit HO-1 mRNA accumulation in response to hypoxia [121]. Interestingly, hypoxic activation of the *ho-1* gene in CHO cells occurred independently of HIF-1 as demonstrated in mutant CHO cells deficient in HIF-1 α [132]. Taken together, these results suggest that while HIF-1 mediates the hypoxic induction of HO-1 in some cell types (i.e. VSMC), it may not be the sole factor involved.

Hyperoxia, or high O₂ tension, used clinically for critical care applications, also activates a stress response *in vitro* and *in vivo*. Hyperoxia causes oxidative injury to the lung, associated with increased production of mitochondrial ROS [133]. Hyperoxia (>95% O₂) increased HO-1 mRNA, protein, and enzymatic activity in the adult rat lung [120], and increased HO activity in neonatal rat lung [134]. Hyperoxia activated *ho-1* transcription *in vitro* in cultured cells of lung origin (epithelial cells, fibroblasts, macrophages, and smooth muscle cells) [120]. In human cell lines the activation of HO-1 by hyperoxia could be augmented by iron loading and diminished in the presence of iron-chelators [89, 135]. Thus, iron appears to represent a general requirement for the activation of *ho-1* gene expression under either high or low O₂ tension.

Regulation of HO-1 expression by heat shock

The rat HO-1 protein classifies as a heat shock protein (HSP-32) since it responds to transcriptional regulation by heat

(42°C); and the 5' regulatory region of its gene contains heat shock elements (HSEs) resembling those described in the promoter regions of heat shock genes (i.e. HSP70) [136–138]. HO-1 mRNA and protein accumulate to a high degree after whole-body hyperthermia (42°C) in rat organs, including the liver, heart, and kidney, and brain [138–139, 140–141]. Heat shock (42°C) increases the transcriptional rate of HO-1 mRNA in cultured rat glioma cells [136].

The rat *ho-1* gene contains two HSEs, HSE1 (–290/–276) and HSE2 (–222/–212) which contain inverted repeats of the core element 5'NGAAN3' [142]. The rat, mouse, and human *ho-1* genes differ in the number, position, and configuration of HSEs in their 5' regulatory regions [142–144]. Both the human and rat HSEs formed complexes with heat inducible nuclear proteins, and conferred heat responsiveness to reporter gene constructs in respective transient transfection assays [136, 145]. Human cell lines, however, generally failed to induce HO-1 in response to heat [101, 145–146].

Signal transduction and transcriptional regulation of ho-1

The signal transduction pathways that operate *ho-1* gene activation under the multiplicity of inducing conditions remain only partially understood. Existing studies often report contradictory data, or cell type-specific and inducer-dependent variations, which are based on known specificities of chemical inhibitors. Mitogen activated protein kinase (MAPK) pathways, including extracellular regulated kinases (ERK) [113, 147] and/or p38 MAPK [113, 147–148], participate in the activation of *ho-1* by inducing xenobiotics. For example, the CdCl₂ induction of *ho-1* transcription in murine MCF-7 cells, could be abolished by the p38 MAPK inhibitor (SB203580) and by dominant negative mutants of p38 α , but not by an ERK kinase (MEK1) inhibitor (PD98059) [148]. Similar MAPK inhibitor studies have demonstrated the requirement for both ERK and p38 MAPK pathways in the NaAsO₂-dependent transcriptional activation of the chicken *ho-1* promoter [147]. In this system, the overexpression of dominant negative forms of Ras, MEK1, and p38 MAPK inhibited transcriptional activation of *ho-1* in response to NaAsO₂ treatment [147]. Both p38 MAPK and ERK pathways participated in *ho-1* activation in HeLa cells following exposure to NO donors [113]. In contrast, *ho-1* activation by NaAsO₂, heme, or CdCl₂ in HeLa cells required tyrosine kinase activity but not ERK or p38 MAPK pathways [149].

The regulation of *ho-1* under hypoxia required p38 MAPK, but not ERK or tyrosine kinase dependent pathways in cardiomyocytes [150]. To the contrary, the p38 MAPK inhibitor SB203580 activated HO-1 mRNA expression under hypoxia in rat PAEC, whereas a MEK1/2 inhibitor (UO126) strongly activated HO-1 under normoxic conditions in the absence of stimuli; indicating that MAPK inhibitors alone may acti-

vate *ho-1* transcription under certain conditions [151]. The over-expression of MAPK kinase kinases (MEKK1, TAK1, and ASK1) induced *ho-1* in HEPG2 cells [152].

The murine *ho-1* gene 5' flanking sequence contains two transcriptional enhancer sequences located at –4kb (E1; formerly SX2) and –10 kb (E2; formerly AB1) of the transcriptional start site [144, 153–155]. These elements maintain basal promoter activity and mediate the induction of *ho-1* by many xenobiotics, including CdCl₂, 12-*O*-tetradecanoylphorbol-13-acetate, endotoxin, heme, and H₂O₂ [144, 153–156]. Both E1 and E2 consist of repeated essential *cis*-acting DNA motifs designated as stress responsive elements (StRE) with the consensus sequence (T/CGCTGAGTCA). Intrinsic to the StRE appears several overlapping consensus sequences for transcription factor binding sites: AP-1, v-maf oncoprotein, and the Cap'n'collar/basic-leucine zipper family of proteins (CNC-bZIP). The latter sequence resembles the anti-oxidant responsive element (GCNNNGTCA) [157].

The StRE elements of E1 are critical for the *ho-1* transcriptional response to CdCl₂ [158]. Transfection studies in L929 cells with candidate transcription factors demonstrated that only members of the CNC/bZIP family of proteins effectively activate an E1 reporter construct, with nuclear regulatory factor-2 (Nrf2) displaying the strongest activity. The over-expression of the dominant negative mutant form of Nrf2 inhibited E1 enhancer activity (and endogenous *ho-1* induction) in response to CdCl₂ and other inducing agents in L929 and MCF-7 cells [148, 157]. Transcription factor ATF4 has recently been identified as the possible binding partner of Nrf2 in regulating *ho-1* transcription, by yeast two-hybrid analysis [159].

The hyperoxia-mediated induction of *ho-1* in RAW 264.7 cells requires E1 and the participation of E2 enhancer regions. The response is mediated by the intrinsic AP-1 elements acting in cooperation with STAT (signal transducer and activator of transcription) elements located within the proximal promoter region [160]. In contrast, the hypoxic activation of *ho-1* in VSMC requires a sequence at –9 kb (hypoxia responsive element) distinct from E1, that contains two functional binding sites for HIF-1 [121].

Heme oxygenase confers protection against oxidative stress *in vitro* and *in vivo*

An increasing body of evidence supports the general hypothesis that HO-1 acts as an inducible mediator of cellular and systemic defenses against oxidative stress, in models of inflammation, ischemia-reperfusion, hypoxia, and hyperoxia-mediated injury. For example, induction of endogenous HO-1 protein with hemoglobin infusion increased survival in a rat model of LPS-induced inflammatory lung injury [161]. Pre-

induction of HO-1 with either LPS or hemoglobin infusion conferred protection in a rat model of renal injury (glycerol-induced rhabdomyolysis) [162–164].

Homozygous *ho-1* null mice (*ho-1^{-/-}*) displayed increased mortality in a model of lung ischemia-reperfusion (I/R). Inhalation CO (0.2%) compensated entirely for the *ho-1* deficiency in *ho-1^{-/-}* mice, and restored survival following I/R to that of the wild-type mice [165]. The proposed mechanism involved the CO/ cGMP-dependent inhibition of plasminogen activator inhibitor-1 (PAI-1) leading to enhanced fibrinolysis [165]. Adenoviral mediated overexpression of HO-1 (AdHO-1) in pigs inhibited vascular cell proliferation and lesion formation in a model of arterial injury. Conversely, HO-1^{+/+} mice subjected to arterial injury displayed increased vascular cell proliferation, and developed hyperplastic lesions in comparison to HO-1^{+/+} controls [166].

Chronic hypoxia treatment (10% O₂) increased right ventricular dilation and caused right myocardial infarction in *ho-1^{-/-}* mice relative to wild-type mice that withstood the treatment [167]. In this model wild-type or *ho-1^{-/-}* mice did not differ in their development of pulmonary hypertension following chronic hypoxia [167]. The induction of HO-1 protein by chemical inducers (i.e. NiCl₂ or hemin) however, prevented the development of pulmonary hypertension in the rat lung as a consequence of chronic hypoxia treatment [168]. Transgenic mice with a lung-specific HO-1 overexpression phenotype, resisted the inflammatory and hypertensive effects of hypoxia [169].

Both HO-1 and HO-2 potentially contribute to pulmonary defenses against high O₂ levels. The adenoviral mediated gene transfer of HO-1 into rat lungs protected against the development of lung apoptosis and inflammation during hyperoxia [5]. Heme oxygenase-2 null mice (*ho-2^{-/-}*), displayed increased sensitivity to the lethal effects of hyperoxia relative to wild-type mice, despite compensatory increases in HO-1, and accumulated iron in their lungs [170]. On the other hand *ho-1^{-/-}* mice had low serum iron anemia, yet accumulated non-heme iron in the kidney and liver, suggesting that iron recycling by HO-1 is critical in maintaining blood iron levels [46]. The mechanism by which HO-1 deficiency resulted in accumulation of tissue iron is unclear. These studies have indicated that animals deficient in either HO-1 and HO-2 display enhanced sensitivity to oxidative stress conditions, and aberrations in the distribution of intra- and extracellular iron [8, 46, 170].

HO-1 also confers protection in animal models of arteriosclerosis, where it may be found in atherosclerotic lesions [171]. The adenoviral-mediated transduction of HO-1 into ApoE deficient mice inhibited the formation of arteriosclerotic plaques relative to control virus transduced mice [172]. Induction of endogenous HO-1 by chemical treatment (hemin) reduced the formation of atherosclerotic lesions in LDL-receptor knockout mice fed high fat diets, relative to untreated or SNPPPIX treated controls [173].

Evidence from *in vitro* studies also supports protective

roles of HO-1. For example, the overexpression of HO-1 in endothelial cells conferred protection against heme and hemoglobin-mediated toxicity [3]. Cultured cerebral granular neurons overexpressing HO-1 displayed resistance to glutamate toxicity relative to wild-type cells [174]. Embryo fibroblasts with the *ho-1^{-/-}* genotype displayed hypersensitivity to heme and H₂O₂ treatment and generated increased intracellular ROS production in response to these agents [8]. Overexpression of HO-1 in lung epithelial cells or rat fetal lung cells conferred resistance against the cytotoxic effects of hyperoxia, associated with growth arrest [4, 9]. The conditional overexpression of HO-1 in cultured L929 fibroblasts inhibited TNF α -induced apoptosis, a phenomenon that could be blocked by inhibitors of HO activity (SnPPPIX), and mimicked by exogenous CO (250 ppm) [7]. Finally, the administration of HO-1 antisense oligonucleotides inhibited the cytoprotective effect of UVA-preconditioning against subsequent lethal UVA exposures in human skin fibroblasts [10].

On the other hand, not all model systems support a protective role for HO-1. Pro-oxidant effects of HO activity have been reported in over-expression systems, related to transient iron overload [24, 175–176]. For example, the susceptibility of HeLa cells to UVA radiation was increased in HO-2 overexpressing strains, when the UVA was applied in combination with a substrate load (heme), in a fashion dependent on heme iron release [175].

Functional significance of carbon monoxide released from the HO reaction

Carbon monoxide

Carbon monoxide is a low molecular weight diatomic gas that occurs ubiquitously in nature as an air pollutant. Environmental CO arises from the oxidation or combustion of organic matter (i.e. wood, coal, gasoline, natural gas, tobacco). Ambient CO concentrations in the lower atmosphere occur in the range of 0.4–1.0 μ L or <1 ppm; which may reach 1–20 ppm in urban areas, and still higher in heavily polluted areas [177–178]. CO is a major component of cigarette smoke, reaching yields of up to 20 mg per cigarette [179]. In man, endogenous CO arises principally from heme degradation (>86%). The remainder arises from other sources that may include lipid peroxidation, and xenobiotic metabolism [177].

Physiological roles for CO involving cGMP-dependent signaling

The field of small gas signal transduction was born with the realization that an endothelial derived relaxing factor responsible for the paracrine regulation of vascular smooth muscle tone, was identical to the diatomic free radical gas NO. The

nitric oxide synthase (NOS) enzymes generate NO during the conversion of L-arginine to L-citrulline. The effects of NO on vasodilation involve the activation of soluble guanylate cyclase (sGC), increasing the production of guanosine 3',5'-cyclic monophosphate (cGMP) [180]. This paradigm led to the proposal that CO, a small gas of similar structure, released directly from heme during HO activity, may function as a soluble messenger molecule in a similar fashion [12, 14–18, 40, 181]. Unlike NO however, CO is not a radical, and therefore is relatively inert by comparison. Both CO and NO stimulate sGC activity *in vitro* by binding to the ferrous heme moiety of the enzyme [12, 182–183]. While NO forms a pentacoordinate complex with the heme of sGC, CO may initially form a hexacoordinate complex [12, 182]. CO has a relatively lower affinity for the heme-iron of sGC than NO, and is one-thousandfold less potent than NO with respect to vasodilation and the *in vitro* activation of sGC [12, 183]. CO signaling may become relevant under oxidative stress or pathophysiological conditions where HO-1 is dramatically induced, and/or where the bioavailability of NO is reduced. Little is known about how CO is mobilized for signaling, apart from two intuitive mechanisms (I) the availability of substrate heme for enzymatic degradation, and (II) the availability of active HO enzymes, a process which in turn may be regulated by the transcriptional activation of the *ho-1* gene by stress, and the possible modulation of *ho-2* by glucocorticoids [18]. Transient fluxes in the free heme pool have been reported following oxidative stress conditions such as UVA (320–380 nm) radiation treatment [184]. Paradoxically, CO may inhibit HO activity in reconstituted microsomal systems, implying that the production of CO may be limited by negative feedback regulation [185].

Physiological roles for CO, which directly involve modulation of cGMP levels, include neurotransmission, vasodilation, the inhibition of platelet aggregation, and anti-proliferative effects on smooth muscle [12, 14–18, 40, 181]. In brain slices, *in situ* hybridization studies demonstrated that the distribution of HO-2 matches that of NADPH cytochrome P-450 reductase and guanylate cyclase [17]. The induction of guanylate cyclase in cultured olfactory neurons by olfactory stimulants can be inhibited by metalloporphyrin inhibitors of HO such as ZnPPiX, but not inhibitors of NOS [17].

Recent studies point to the involvement of CO in cardiovascular signaling. In the rat, both whole body hyperthermia (42°C), or renal I/R triggered the elevation of cGMP levels in the heart in parallel with the transcriptional induction of HO-1 [141, 186]. In VSMC, an elevation of cGMP occurred following exogenous CO treatment [14]. cGMP increased also following hypoxia in association with HO-1 elevation, an effect that could be inhibited by SnPPiX, and the CO scavenger hemoglobin, but not inhibitors of NOS [14]. VSMC derived CO had paracrine effects on endothelial cells in co-culture, stimulating the production of endothelial cGMP, and suppressing the expression of endothelial-derived mitogens (PDGF, endothelin

1) [15]. Both exogenously applied CO, or hypoxia induced CO had antiproliferative effects on VSMC, associated with elevation of cGMP, and inhibition of transcription factor E2F, a regulator of cell cycle control [16]. AdHO-1 infection in VSMC stimulated cGMP production, and inhibited cell proliferation *in vitro* by G₁/G₀ arrest, which required the G1 cyclin dependent protein kinase inhibitor p21^{cip1} [166].

The involvement of endothelial derived CO in NO-independent vasodilation has been suggested in inhibitor studies. In the presence of the NOS inhibitor N ω -nitro-L-arginine-methyl-ester, (L-NAME), the HO inhibitor SnPPiX further inhibits vasorelaxation elicited by acetylcholine in porcine aortic rings [40]. Conversely, the endothelium-dependent contractile response to phenylephrine in thoracic aortic rings was more pronounced in the presence of both ZnPPiX and N ω -nitro-L-arginine (NNA); than in the presence of NNA alone [187]. In this system, exogenously applied CO relaxed the aortic rings in a cGMP-dependent fashion. Overexpression of HO-1 by AdHO-1 infection in pigs inhibited phenylephrine-dependent vasoconstriction in isolated aortic rings. Furthermore, AdHO-1 infection induced cGMP production in VSMC. The effects of HO-1 expression on vasoconstriction and cGMP production were subject to inhibition by ZnPPiX; but occurred in the presence of NOS inhibitors (i.e. L-NNA, L-NAME) [166]. Thus, these effects are dependent on heme degradation and independent of NOS activity or NO generation.

Exogenous CO or heme treatment dilated pig cerebral arterioles, the latter effect which could be blocked by chromium mesoporphyrin [188]. ZnPPiX, but not NOS inhibitors, inhibited smooth muscle relaxation in the opossum internal anal sphincter produced by nonadrenergic noncholinergic (NANC) nerve stimulation [189]. In isolated perfused rat liver, ZnPPiX diminished CO levels detectable in the effluent, and increased the perfusion pressure under the constant flow conditions. These effects were reversed by the addition of CO or cGMP analogues in the perfusate [190].

These studies support the existence of CO/cGMP signal transduction cascades and their possible regulation by heme oxygenases, as potential pathways governing physiological processes. It remains possible, however, that a fraction of endogenous CO originating from non-heme sources may contribute to a corresponding fraction of cGMP production. More discussion on the significance of CO in the cardiovascular system under normal and pathophysiological states appears in other recent reviews [13, 191].

Carbon monoxide (CO): An anti-inflammatory mediator

HO-1 exerts a novel anti-inflammatory effect mediated by carbon monoxide (CO) generated in the HO reaction [6]. The

effectiveness of bacterial lipopolysaccharide (LPS) (heretofore 1 $\mu\text{g/ml}$), to stimulate the production of the pro-inflammatory cytokine $\text{TNF}\alpha$, was inhibited in transfected RAW 264.7 macrophage cells overexpressing HO-1, compared to that in control transfectants. Exogenously administered CO (heretofore 250 ppm) inhibited the production of $\text{TNF}\alpha$ in wild-type RAW 264.7 cells after LPS treatment, indicating that CO can substitute for HO activity in mediating these effects. The treatment of RAW 264.7 cells with exogenous CO prior to LPS treatment inhibited the expression of additional pro-inflammatory cytokines (i.e. IL-1 β , and the macrophage inflammatory protein- β , MIP-1 β), whereas increased the production of the anti-inflammatory cytokine interleukin-10 (IL-10). The LPS mediated stimulation of pro-inflammatory cytokines in macrophages involves the activation of MAPK signaling pathways [192–195]. LPS treatment activated the p38, ERK1/ERK2 and c-JUN N-terminal kinase, (JNK) pathways in RAW 264.7 macrophages. In the presence of LPS, CO increased p38 MAPK activation, but did not modulate ERK1/ERK2 and JNK. Of the MAP kinase kinases (MKK): (MKK3, MKK4, and MKK6) that activate p38 MAPK [196–197], CO enhanced the LPS-mediated stimulation of MKK3 and MKK6 in RAW 264.7 cells. CO treatment did not significantly modulate cGMP production in RAW 264.7 macrophages, but dramatically increased cGMP levels in control smooth muscle cells. Pretreatment of the RAW 264.7 macrophages with a non-hydrolysable cGMP analog or L-NAME did not compromise the ability of CO to inhibit LPS-inducible $\text{TNF}\alpha$ production.

These anti-inflammatory effects of CO were substantiated *in vivo*, in experiments where mice received injections of LPS (heretofore 1 mg/kg) with or without CO pretreatment (heretofore 250 ppm). CO dose-dependently inhibited LPS-inducible serum $\text{TNF}\alpha$ levels and increased LPS-inducible IL-10 production. The responsiveness of $\text{TNF}\alpha$ to LPS treatment appeared downregulated in MKK3^{+/−} mice compared to wild-type mice. CO failed to further downregulate $\text{TNF}\alpha$ levels or upregulate IL-10 levels in LPS treated MKK3^{+/−} mice. In IL-10^{+/−} mice, CO inhibited $\text{TNF}\alpha$ levels within the first hour of LPS treatment to a similar extent than in wild-type mice, excluding a role for IL-10 in the early anti-inflammatory effects of CO [6].

These results, taken together, demonstrate that CO exerts anti-inflammatory effects by inhibiting the synthesis of the pro-inflammatory cytokines under inducing conditions, by a mechanism that involves stimulation of the MKK3/p38 MAPK pathway, but excludes sGC/cGMP, iNOS, or NO-dependent signaling. The direct physical target of CO in initiating this pathway remains obscure. Various intracellular hemoproteins (i.e. cytochrome p-450, cytochrome c oxidase, NAD(P)H: oxidase, peroxidases, and others) may serve as targets for CO binding [19–22, 198–199]. Future research may focus on elucidating the functional significance (with respect to cell signaling) of CO-hemoprotein interactions *in vivo*.

Cytoprotective and anti-inflammatory effects of carbon monoxide in oxidative lung injury: Involvement of the MKK3/p38 MAPK pathway

CO, through anti-inflammatory action, protects the lung in a model of hyperoxia-induced lung injury [11], which evokes symptoms in mice similar to human acute respiratory distress syndrome (ARDS) [200]. Mice subjected to continuous hyperoxia treatment (heretofore >95% O₂), displayed signs of lung injury by 64–72 h, and all died within 90–100 h of exposure. The presence of CO (heretofore, 250 ppm) initiated prior to the hyperoxia, prolonged the survival of mice in the hyperoxic environment, increasing the LD₅₀ to 128 h exposure. CO inhibited the appearance of markers of lung injury associated with hyperoxia (i.e. hemorrhage, fibrin deposition, edema, and protein accumulation in the airway), as well as markers of oxidative damage (i.e. lung lipid peroxidation) [11]. CO also inhibited the influx of neutrophils into the airways associated with hyperoxia treatment, as measured in bronchoalveolar lavage fluid.

Hyperoxia induced the expression of proinflammatory cytokines including $\text{TNF}\alpha$, IL-1 β , and IL-6, by 84 h of exposure and activated stress kinases in lung tissue including ERK1/2, JNK, P38/MAPK and MKK3/MKK6. The protection afforded by CO treatment against the lethal effects of hyperoxia correlated with the inhibited expression of the pro-inflammatory cytokines, $\text{TNF}\alpha$, IL-1 β and IL-6.

MKK3^{+/−} mice, or wild-type mice injected with the selective inhibitor of p38 α/β MAPK (SB203580), displayed the accelerated manifestation of tissue damage markers (with the exception of neutrophil influx) and increased sensitivity to the lethal effects of hyperoxia, relative to untreated wild-type mice. Cytokine mRNA ($\text{TNF}\alpha$, IL-1 β and IL-6) expression in response to hyperoxia appeared earlier in the MKK3^{+/−} mice relative the wild-type mice exposed to continuous hyperoxia. CO failed to inhibit the expression of the pro-inflammatory cytokines in the MKK3^{+/−} mice, and furthermore failed to confer protection or extend survival against hyperoxia in MKK3^{+/−} mice or in wild-type mice injected with SB203580. On the other hand, JNK^{+/−} mice behaved as wild-type mice with respect to the anti-inflammatory effects of CO [11].

The CO treatment of A549 lung epithelial cells *in vitro* increased MKK3 activation, and specifically the β -isoform of p38. The presence of CO increased the survival of A549 cells grown in continuous hyperoxia, relative to cells exposed to hyperoxia alone. Treatment with the inhibitor of p38 α/β MAPK or transient transfection with dominant negative mutants of p38 β or MKK3 abolished the cytoprotective effect of CO against hyperoxia. Currently no studies support the selective activation of antioxidant enzymes or stress proteins as an underlying mechanism for the anti-inflammatory properties of CO *in vivo*. However, the treatment of endothelial cells *in vitro* with exogenous CO (100 ppm) stimulated the expression of

manganese superoxide dismutase (MnSOD) and HO activity [201]. In summary, these experiments demonstrate that CO protects against the lethal and inflammatory effects of hyperoxia *in vivo* and *in vitro*, by downregulating the expression of pro-inflammatory cytokines, through a mechanism dependent on activation of the p38 β / MKK3 pathway [11].

Summary

The functional significance of heme oxygenase-1, which provides the rate-limiting step in heme degradation, and whose induction represents a general response to cellular stress, has remained a subject of debate for decades [23–24, 37, 202]. The overwhelming evidence described above supports the conclusion that HO-1 expression confers protection in animal models of oxidative stress. These studies taken together, suggest that HO-1 expression may have therapeutic value in gene therapy approaches.

Attempts to explain the cytoprotective action of HO-1 have implicated possible roles for all the products of HO-activity including redox active iron and bile pigments [23–24]. CO, formerly regarded as a toxic elimination product of the HO reaction has taken on a new significance as a possible autocrine and paracrine signaling molecule. CO regulates vascular and neural processes by modulation of cGMP production [18]. Recent work has identified anti-inflammatory and anti-apoptotic properties of HO-derived CO [6, 11]. In animal models of lung oxidative stress, including hyperoxia and ischemia/reperfusion, exogenously applied CO may apparently substitute for HO-1 expression with regard to protection [6, 165]. Such studies point to a possible therapeutic use of inhalation CO in inflammatory disease states.

References

1. Tenhunen R, Marver HS, Schmid R: The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. *Proc Natl Acad Sci USA* 61: 748–755, 1968
2. Tenhunen R, Marver HS, Schmid R: Microsomal heme oxygenase. Characterization of the enzyme. *J Biol Chem* 244: 6388–6394, 1969
3. Abraham NG, Lavrovsky Y, Schwartzman ML, Stoltz RA, Levere RD, Gerritsen ME, Shibahara S, Kappas A: Transfection of the human heme oxygenase gene into rabbit coronary microvessel endothelial cells: Protective effect against heme and hemoglobin toxicity. *Proc Natl Acad Sci USA* 92: 6798–6802, 1995
4. Lee PJ, Alam J, Wiegand GW, Choi AM: Overexpression of heme oxygenase-1 in human pulmonary epithelial cells results in cell growth arrest and increased resistance to hyperoxia. *Proc Natl Acad Sci USA* 93: 10393–10398, 1996
5. Otterbein LE, Kolls JK, Mantell LL, Cook JL, Alam J, Choi AM: Exogenous administration of heme oxygenase-1 by gene transfer provides protection against hyperoxia-induced lung injury. *J Clin Invest* 103: 1047–10554, 1999
6. Otterbein LE, Bach FH, Alam J, Soares M, Tao LH, Wysk M, Davis RJ, Flavell RA, Choi AM: Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. *Nat Med* 6: 422–428, 2000
7. Petrache I, Otterbein LE, Alam J, Wiegand GW, Choi AM: Heme oxygenase-1 inhibits TNF-alpha-induced apoptosis in cultured fibroblasts. *Am J Physiol Lung Cell Mol Physiol* 278: L312–L319, 2000
8. Poss KD, Tonegawa S: Reduced stress defense in heme oxygenase 1-deficient cells. *Proc Natl Acad Sci USA* 94: 10925–10930, 1997
9. Suttner DM, Sridhar K, Lee CS, Tomura T, Hansen TN, Dennery PA: Protective effects of transient HO-1 overexpression on susceptibility to oxygen toxicity in lung cells. *Am J Physiol* 276: L443–L451, 1999
10. Vile GF, Basu-Modak S, Waltner C, Tyrrell RM: Heme oxygenase 1 mediates an adaptive response to oxidative stress in human skin fibroblasts. *Proc Natl Acad Sci USA* 91: 2607–2610, 1994
11. Otterbein LE, Otterbein SL, Morse DE, Fearn C, Ulevitch RJ, Gram H, Padova FD, Zurini M, Knickelbein R, Davis RJ, Flavell RA, Choi AM: MKK3 mitogen activated protein kinase pathway mediates carbon monoxide-induced protection against oxidant-induced lung injury (unpublished)
12. Furchgott RF, Jothianandan D: Endothelium-dependent and -independent vasodilation involving cyclic GMP: Relaxation induced by nitric oxide, carbon monoxide and light. *Blood Vessels* 28: 52–61, 1991
13. Durante W, Schafer AI: Carbon monoxide and vascular cell function (Review). *Int J Mol Med* 2: 255–262, 1998
14. Morita T, Perrella MA, Lee ME, Kourembanas S: Smooth muscle cell-derived carbon monoxide is a regulator of vascular cGMP. *Proc Natl Acad Sci USA* 92: 1475–1479, 1995
15. Morita T, Kourembanas S: Endothelial cell expression of vasoconstrictors and growth factors is regulated by smooth muscle cell-derived carbon monoxide. *J Clin Invest* 96: 2676–2682, 1995
16. Morita T, Mitsialis SA, Koike H, Liu Y, Kourembanas S: Carbon monoxide controls the proliferation of hypoxic vascular smooth muscle cells. *J Biol Chem* 272: 32804–32809, 1997
17. Verma A, Hirsch DJ, Glatt CE, Ronnett GV, Snyder SH: Carbon monoxide: A putative neural messenger. *Science* 259: 381–384, 1993
18. Maines MD: The heme oxygenase system: A regulator of second messenger gases. *Annu Rev Pharmacol Toxicol* 37: 517–554, 1997
19. Volpe JA, O'Toole MC, Caughey WS: Quantitative infrared spectroscopy of CO complexes of cytochrome c oxidase, hemoglobin and myoglobin: Evidence for one CO per heme. *Biochem Biophys Res Commun* 62: 48–53, 1975
20. Guengerich FP, Ballou DP, Coon MJ: Purified liver microsomal cytochrome P-450. Electron-accepting properties and oxidation-reduction potential. *J Biol Chem* 250: 7405–7414, 1975
21. Cross AR, Higson FK, Jones OTG, Harper AM, Segal AW: The enzymic reduction and kinetics of oxidation of cytochrome b₂₄₅ of neutrophils. *Biochem J* 204: 479–485, 1982
22. Stevenson TH, Gutierrez AF, Alderton WK, Lian L, Scrutton NS: Kinetics of CO binding to the haem domain of murine inducible nitric oxide synthase: Differential effects of haem domain ligands. *Biochem J* 358: 201–208, 2001
23. Otterbein LE, Choi AM: Heme oxygenase: Colors of defense against cellular stress. *Am J Physiol Lung Cell Mol Physiol* 279: L1029–L1037, 2000
24. Ryter SW, Tyrrell RM: The heme synthesis and degradation pathways: Role in oxidant sensitivity. Heme oxygenase has both pro- and antioxidant properties. *Free Radic Biol Med* 28: 289–309, 2000

25. Keyse SM, Tyrrell RM: Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite. *Proc Natl Acad Sci USA* 86: 99–103, 1989
26. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN: Bilirubin is an antioxidant of possible physiological importance. *Science* 235: 1043–1046, 1987
27. Eisenstein RS, Garcia-Mayol D, Pettingell W, Munro HN: Regulation of ferritin and heme oxygenase synthesis in rat fibroblasts by different forms of iron. *Proc Natl Acad Sci USA* 88: 688–692, 1991
28. Vile GF, Tyrrell RM: Oxidative stress resulting from ultraviolet A irradiation of human skin fibroblasts leads to a heme oxygenase-dependent increase in ferritin. *J Biol Chem* 268: 14678–14681, 1993
29. Ferris CD, Jaffrey SR, Sawa A, Takahashi M, Brady SD, Barrow RK, Tysoe SA, Wolosker H, Baranano DE, Dore S, Poss KD, Snyder SH: Haem oxygenase-1 prevents cell death by regulating cellular iron. *Nat Cell Biol* 1: 152–157, 1999
30. Eisenstein RS, Munro HN: Translational regulation of ferritin synthesis by iron. *Enzyme* 44: 42–58, 1990
31. Hentze MW, Kuhn LC: Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. *Proc Natl Acad Sci USA* 93: 8175–8182, 1996
32. Balla G, Jacob HS, Balla J, Rosenberg M, Nath K, Apple F, Eaton JW, Vercellotti GM: Ferritin: A cytoprotective antioxidant stratagem of endothelium. *J Biol Chem* 267: 18148–18153, 1992
33. Yoshida T, Noguchi M, Kikuchi G: Oxygenated form of heme: heme oxygenase complex and requirement for second electron to initiate heme degradation from the oxygenated complex. *J Biol Chem* 255: 4418–4420, 1980
34. Yoshida T, Noguchi M, Kikuchi G: The step of carbon monoxide liberation in the sequence of heme degradation catalyzed by the reconstituted microsomal heme oxygenase system. *J Biol Chem* 257: 9345–9348, 1982
35. Tenhunen R, Ross ME, Marver HS, Schmid R: Reduced nicotinamide-adenine dinucleotide phosphate dependent biliverdin reductase: Partial purification and characterization. *Biochemistry* 9: 298–303, 1970
36. Cruse I, Maines MD: Evidence suggesting that the two forms of heme oxygenase are products of different genes. *J Biol Chem* 263: 3348–3353, 1988
37. Maines MD: *Heme Oxygenase: Clinical Applications and Functions*. CRC Press, Boca Raton, FL, 1992
38. Maines MD, Trakshel GM, Kutty RK: Characterization of two constitutive forms of rat liver microsomal heme oxygenase. Only one molecular species of the enzyme is inducible. *J Biol Chem* 261: 411–419, 1986
39. McCoubrey WK Jr, Huang TJ, Maines MD: Isolation and characterization of a cDNA from the rat brain that encodes hemoprotein heme oxygenase-3. *Eur J Biochem* 247: 725–732, 1997
40. Zakhary R, Gaine SP, Dinerman JL, Ruat M, Flavahan NA, Snyder SH: Heme oxygenase 2: Endothelial and neuronal localization and role in endothelium-dependent relaxation. *Proc Natl Acad Sci USA* 93: 795–798, 1996
41. Raju VS, McCoubrey WK Jr, Maines MD: Regulation of heme oxygenase-2 by glucocorticoids in neonatal rat brain: Characterization of a functional glucocorticoid response element. *Biochim Biophys Acta* 1351: 89–104, 1997
42. Maines MD: Corticosterone promotes increased heme oxygenase-2 protein and transcript expression in the newborn rat brain. *Brain Res* 722: 83–94, 1996
43. Ding Y, McCoubrey WK Jr, Maines MD: Interaction of heme oxygenase-2 with nitric oxide donors. Is the oxygenase an intracellular ‘sink’ for NO? *Eur J Biochem* 264: 854–861, 1999
44. Huang TJ, McCoubrey WK Jr, Maines MD: Heme oxygenase-2 interaction with metalloporphyrins: Function of heme regulatory motifs. *Antioxid Redox Signal* 3: 685–696, 2001
45. Maines MD: Heme oxygenase: Function, multiplicity, regulatory mechanisms, and clinical applications. *FASEB J* 2: 2557–2568, 1988
46. Poss KD, Tonegawa S: Heme oxygenase 1 is required for mammalian iron reutilization. *Proc Natl Acad Sci USA* 94: 10919–10924, 1997
47. Keyse SM, Tyrrell RM: Both near ultraviolet radiation and the oxidizing agent hydrogen peroxide induce a 32-kDa stress protein in normal human skin fibroblasts. *J Biol Chem* 262: 14821–14825, 1987
48. Alam J, Shibahara S, Smith A: Transcriptional activation of the heme oxygenase gene by heme and cadmium in mouse hepatoma cells. *J Biol Chem* 264: 6371–6375, 1989
49. Cantoni L, Rossi C, Rizzardini M, Gadina M, Ghezzi P: Interleukin-1 and tumour necrosis factor induce hepatic haem oxygenase. Feedback regulation by glucocorticoids. *Biochem J* 279 (Pt 3): 891–894, 1991
50. Mitani K, Fujita H, Kappas A, Sassa S: Heme oxygenase is a positive acute-phase reactant in human Hep3B hepatoma cells. *Blood* 79: 1255–1259, 1992
51. Rizzardini M, Terao M, Falciani F, Cantoni L: Cytokine induction of haem oxygenase mRNA in mouse liver. Interleukin 1 transcriptionally activates the haem oxygenase gene. *Biochem J* 290 (Pt 2): 343–347, 1993
52. Terry CM, Cliekman JA, Hoidal JR, Callahan KS: Effect of tumor necrosis factor-alpha and interleukin-1 alpha on heme oxygenase-1 expression in human endothelial cells. *Am J Physiol* 274: H883–H891, 1998
53. Terry CM, Cliekman JA, Hoidal JR, Callahan KS: TNF-alpha and IL-1alpha induce heme oxygenase-1 via protein kinase C, Ca²⁺, and phospholipase A2 in endothelial cells. *Am J Physiol* 276: H1493–H1501, 1999
54. Camhi SL, Alam J, Otterbein L, Sylvester SL, Choi AM: Induction of heme oxygenase-1 gene expression by lipopolysaccharide is mediated by AP-1 activation. *Am J Respir Cell Mol Biol* 13: 387–398, 1995
55. Camhi SL, Alam J, Wiegand GW, Chin BY, Choi AM: Transcriptional activation of the HO-1 gene by lipopolysaccharide is mediated by 5' distal enhancers: Role of reactive oxygen intermediates and AP-1. *Am J Respir Cell Mol Biol* 18: 226–234, 1998
56. Gems D, Woo CH, Fudenberg HH, Schmid R: Stimulation of heme oxygenase in macrophages and liver by endotoxin. *J Clin Invest* 53: 647–651, 1974
57. Kurata S, Matsumoto M, Tsuji Y, Nakajima H: Lipopolysaccharide activates transcription of the heme oxygenase gene in mouse M1 cells through oxidative activation of nuclear factor kappa B. *Eur J Biochem* 239: 566–571, 1996
58. Rizzardini M, Carelli M, Cabello Porras MR, Cantoni L: Mechanisms of endotoxin-induced haem oxygenase mRNA accumulation in mouse liver: Synergism by glutathione depletion and protection by N-acetylcysteine. *Biochem J* 304 (Pt 2): 477–483, 1994
59. Durante W, Peyton KJ, Schafer AI: Platelet-derived growth factor stimulates heme oxygenase-1 gene expression and carbon monoxide production in vascular smooth muscle cells. *Arterioscler Thromb Vasc Biol* 19: 2666–2672, 1999
60. Kutty RK, Nagineni CN, Kutty G, Hooks JJ, Chader GJ, Wiggert B: Increased expression of heme oxygenase-1 in human retinal pig-

- ment epithelial cells by transforming growth factor-beta. *J Cell Physiol* 159: 371–378, 1994
61. Foresti R, Clark JE, Green CJ, Motterlini R: Thiol compounds interact with nitric oxide in regulating heme oxygenase-1 induction in endothelial cells. Involvement of superoxide and peroxynitrite anions. *J Biol Chem* 272: 18411–18417, 1997
 62. Hartsfield CL, Alam J, Cook JL, Choi AM: Regulation of heme oxygenase-1 gene expression in vascular smooth muscle cells by nitric oxide. *Am J Physiol* 273: L980–L988, 1997
 63. Motterlini R, Foresti R, Intaglietta M, Winslow RM: NO-mediated activation of heme oxygenase: Endogenous cytoprotection against oxidative stress to endothelium. *Am J Physiol* 270: H107–H114, 1996
 64. Yee EL, Pitt BR, Billiar TR, Kim YM: Effect of nitric oxide on heme metabolism in pulmonary artery endothelial cells. *Am J Physiol* 271: L512–L518, 1996
 65. Durante W, Kroll MH, Christodoulides N, Peyton KJ, Schafer AI: Nitric oxide induces heme oxygenase-1 gene expression and carbon monoxide production in vascular smooth muscle cells. *Circ Res* 80: 557–564, 1997
 66. Marquis JC, Demple B: Complex genetic response of human cells to sublethal levels of pure nitric oxide. *Cancer Res* 58: 3435–3440, 1998
 67. Hiwasa T, Fujimura S, Sakiyama S: Tumor promoters increase the synthesis of a 32,000-dalton protein in BALB/c 3T3 cells. *Proc Natl Acad Sci USA* 79: 1800–1804, 1982
 68. Hiwasa T, Sakiyama S: Increase in the synthesis of a Mr 32,000 protein in BALB/c 3T3 cells after treatment with tumor promoters, chemical carcinogens, metal salts, and heat shock. *Cancer Res* 46: 2474–2481, 1986
 69. Kageyama H, Hiwasa T, Tokunaga K, Sakiyama S: Isolation and characterization of a complementary DNA clone for a Mr 32,000 protein which is induced with tumor promoters in BALB/c 3T3 cells. *Cancer Res* 48: 4795–4798, 1988
 70. Kurata S, Nakajima H: Transcriptional activation of the heme oxygenase gene by TPA in mouse M1 cells during their differentiation to macrophage. *Exp Cell Res* 191: 89–94, 1990
 71. Applegate LA, Luscher P, Tyrrell RM: Induction of heme oxygenase: A general response to oxidant stress in cultured mammalian cells. *Cancer Res* 51: 974–978, 1991
 72. Tyrrell RM: Activation of mammalian gene expression by the UV component of sunlight – from models to reality. *Bioessays* 1996 18: 139–148, 1996
 73. Keyse SM, Applegate LA, Tromvoukis Y, Tyrrell RM: Oxidant stress leads to transcriptional activation of the human heme oxygenase gene in cultured skin fibroblasts. *Mol Cell Biol* 10: 4967–4969, 1990
 74. Basu-Modak S, Tyrrell RM: Singlet oxygen: A primary effector in the ultraviolet A/near-visible light induction of the human heme oxygenase gene. *Cancer Res* 53: 4505–4510, 1993
 75. Ryter SW, Tyrrell RM: Singlet molecular oxygen ($(^1O_2)$): A possible effector of eukaryotic gene expression. *Free Radic Biol Med* 24: 1520–1534, 1998
 76. Gomer CJ, Luna M, Ferrario A, Rucker N: Increased transcription and translation of heme oxygenase in Chinese hamster fibroblasts following photodynamic stress or Photofrin II incubation. *Photochem Photobiol* 53: 275–279, 1991
 77. Lautier D, Luscher P, Tyrrell RM: Endogenous glutathione levels modulate both constitutive and UVA radiation/hydrogen peroxide inducible expression of the human heme oxygenase gene. *Carcinogenesis* 13: 227–232, 1992
 78. Tyrrell RM: Approaches to define pathways of redox regulation of a eukaryotic gene: The heme oxygenase 1 example. *Methods* 11: 313–318, 1997
 79. Tyrrell RM, Pidoux M: Endogenous glutathione protects human skin fibroblasts against the cytotoxic action of UVB, UVA and near-visible radiations. *Photochem Photobiol* 44: 561–564, 1986
 80. Tyrrell RM, Pidoux M: Correlation between endogenous glutathione content and sensitivity of cultured human skin cells to radiation at defined wavelengths in the solar ultraviolet range. *Photochem Photobiol* 47: 405–412, 1988
 81. Saunders EL, Maines MD, Meredith MJ, Freeman ML: Enhancement of heme oxygenase-1 synthesis by glutathione depletion in Chinese hamster ovary cells. *Arch Biochem Biophys* 288: 368–373, 1991
 82. Taketani S, Sato H, Yoshinaga T, Tokunaga R, Ishii T, Bannai S: Induction in mouse peritoneal macrophages of 34 kDa stress protein and heme oxygenase by sulfhydryl-reactive agents. *J Biochem (Tokyo)* 108: 28–32, 1990
 83. Borger DR, Essig DA: Induction of HSP 32 gene in hypoxic cardiomyocytes is attenuated by treatment with N-acetyl-L-cysteine. *Am J Physiol* 274: H965–H973, 1998
 84. Camhi SL, Alam J, Wiegand GW, Chin BY, Choi AM: Transcriptional activation of the HO-1 gene by lipopolysaccharide is mediated by 5' distal enhancers: Role of reactive oxygen intermediates and AP-1. *Am J Respir Cell Mol Biol* 18: 226–234, 1998
 85. Gong Q, Hart BA: Effect of thiols on cadmium-induced expression of metallothionein and other oxidant stress genes in rat lung epithelial cells. *Toxicology* 119: 179–191, 1997
 86. Ryter SW, Si M, Lai CC, Su CY: Regulation of endothelial heme oxygenase activity during hypoxia is dependent on chelatable iron. *Am J Physiol Heart Circ Physiol* 279: H2889–H2897, 2000
 87. Shan Y, Lambrecht RW, Hong LT, Bonkovsky HL: Effects of phenylarsine oxide on expression of heme oxygenase-1 reporter constructs in transiently transfected cultures of chick embryo liver cells. *Arch Biochem Biophys* 372: 224–229, 1999
 88. Keyse SM, Tyrrell RM: Induction of the heme oxygenase gene in human skin fibroblasts by hydrogen peroxide and UVA (365 nm) radiation: Evidence for the involvement of the hydroxyl radical. *Carcinogenesis* 11: 787–791, 1990
 89. Fogg S, Agarwal A, Nick HS, Visner GA: Iron regulates hyperoxia-dependent human heme oxygenase 1 gene expression in pulmonary endothelial cells. *Am J Respir Cell Mol Biol* 20: 797–804, 1999
 90. Panchenko MV, Farber HW, Korn JH: Induction of heme oxygenase-1 by hypoxia and free radicals in human dermal fibroblasts. *Am J Physiol Cell Physiol* 278: C92–C101, 2000
 91. Aust SD, Morehouse LA, Thomas CE: Role of metals in oxygen radical reactions. *J Free Radic Biol Med* 1: 3–25, 1985
 92. Balla G, Vercellotti GM, Eaton JW, Jacob HS: Iron loading of endothelial cells augments oxidant damage. *J Lab Clin Med* 116: 546–554, 1990
 93. Wang GL, Semenza GL: Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: Implications for models of hypoxia signal transduction. *Blood* 82: 3610–3615, 1993
 94. Kuhn LC: Iron and gene expression: Molecular mechanisms regulating cellular iron homeostasis. *Nutr Rev* 56: s11–s19, 1998
 95. Maines MD, Kappas A: Metals as regulators of heme metabolism. *Science* 198: 1215–1221, 1977
 96. Sardana MK, Drummond GS, Sassa S, Kappas A: The potent heme oxygenase inducing action of arsenic and parasiticidal arsenicals. *Pharmacology* 23: 247–253, 1981
 97. Caltabiano MM, Koestler TP, Poste G, Greig RG: Induction of 32- and 34-kDa stress proteins by sodium arsenite, heavy metals, and thiol-reactive agents. *J Biol Chem* 261: 13381–13386, 1986

98. Johnston D, Oppermann H, Jackson J, Levinson W: Induction of four proteins in chick embryo cells by sodium arsenite. *J Biol Chem* 255: 6975–6980, 1980
99. Mitani K, Fujita H, Sassa S, Kappas A: Activation of heme oxygenase and heat shock protein 70 genes by stress in human hepatoma cells. *Biochem Biophys Res Commun* 166: 1429–1434, 1990
100. Taketani S, Kohno H, Yoshinaga T, Tokunaga R: Induction of heme oxygenase in rat hepatoma cells by exposure to heavy metals and hyperthermia. *Biochem Int* 17: 665–672, 1988
101. Taketani S, Kohno H, Yoshinaga T, Tokunaga R: The human 32-kDa stress protein induced by exposure to arsenite and cadmium ions is heme oxygenase. *FEBS Lett* 245: 173–176, 1989
102. Freeman ML, Meredith MJ: Glutathione conjugation and induction of a 32,000 dalton stress protein. *Biochem Pharmacol* 38: 299–304, 1989
103. Shelton KR, Egle PM, Todd JM: Evidence that glutathione participates in the induction of a stress protein. *Biochem Biophys Res Commun* 134: 492–498, 1986
104. Kappas A, Drummond GS: Control of heme and cytochrome P-450 metabolism by inorganic metals, organometals and synthetic metalloporphyrins. *Environ Health Perspect* 57: 301–306, 1984
105. Maines MD, Sinclair P: Cobalt regulation of heme synthesis and degradation in avian embryo liver cell culture. *J Biol Chem* 252: 219–223, 1977
106. Mitani K, Fujita H, Fukuda Y, Kappas A, Sassa S: The role of inorganic metals and metalloporphyrins in the induction of haem oxygenase and heat-shock protein 70 in human hepatoma cells. *Biochem J* 290 (Pt 3): 819–825, 1993
107. Abe T, Yamamoto O, Gotoh S, Yan Y, Todaka N, Higashi K: Cadmium-induced mRNA expression of Hsp32 is augmented in metallothionein-I and -II knock-out mice. *Arch Biochem Biophys* 382: 81–88, 2000
108. Abraham NG, Levere RD, Lin JH, Beru N, Hermine O, Goldwasser E: Co-regulation of heme oxygenase and erythropoietin genes. *J Cell Biochem* 47: 43–48, 1991
109. Lin JH, Villalon P, Martasek P, Abraham NG: Regulation of heme oxygenase gene expression by cobalt in rat liver and kidney. *Eur J Biochem* 192: 577–582, 1990
110. Sardana MK, Kappas A: Dual control mechanism for heme oxygenase: Tin(IV)-protoporphyrin potently inhibits enzyme activity while markedly increasing content of enzyme protein in liver. *Proc Natl Acad Sci USA* 84: 2464–2468, 1987
111. Smith A, Alam J, Escriba PV, Morgan WT: Regulation of heme oxygenase and metallothionein gene expression by the heme analogs, cobalt-, and tin-protoporphyrin. *J Biol Chem* 268: 7365–7371, 1993
112. Wink DA, Mitchell JB: Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. *Free Radic Biol Med* 25: 434–456, 1998
113. Chen K, Maines MD: Nitric oxide induces heme oxygenase-1 via mitogen-activated protein kinases ERK and p38. *Cell Mol Biol (Noisy-le-grand)* 46: 609–617, 2000
114. Takahashi K, Hara E, Suzuki H, Sasano H, Shibahara S: Expression of heme oxygenase isozyme mRNAs in the human brain and induction of heme oxygenase-1 by nitric oxide donors. *J Neurochem* 67: 482–489, 1996
115. Bouton C, Demple B: Nitric oxide-inducible expression of heme oxygenase-1 in human cells. Translation-independent stabilization of the mRNA and evidence for direct action of nitric oxide. *J Biol Chem* 275: 32688–32693, 2000
116. Foresti R, Sarathchandra P, Clark JE, Green CJ, Motterlini R: Peroxynitrite induces haem oxygenase-1 in vascular endothelial cells: A link to apoptosis. *Biochem J* 339 (Pt 3): 729–736, 1999
117. Sharma HS, Maulik N, Gho BC, Das DK, Verdouw PD: Coordinated expression of heme oxygenase-1 and ubiquitin in the porcine heart subjected to ischemia and reperfusion. *Mol Cell Biochem* 157: 111–116, 1996
118. Downard PJ, Wilson MA, Spain DA, Matheson PJ, Siow Y, Garrison RN: Heme oxygenase-dependent carbon monoxide production is a hepatic adaptive response to sepsis. *J Surg Res* 71: 7–12, 1997
119. Fukuda Y, Sassa S: Effect of interleukin-11 on the levels of mRNAs encoding heme oxygenase and haptoglobin in human HepG2 hepatoma cells. *Biochem Biophys Res Commun* 193: 297–302, 1993
120. Lee PJ, Alam J, Sylvester SL, Inamdar N, Otterbein L, Choi AM: Regulation of heme oxygenase-1 expression *in vivo* and *in vitro* in hyperoxic lung injury. *Am J Respir Cell Mol Biol* 14: 556–568, 1996
121. Lee PJ, Jiang BH, Chin BY, Iyer NV, Alam J, Semenza GL, Choi AM: Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. *J Biol Chem* 272: 5375–5381, 1997
122. Murphy BJ, Laderoute KR, Short SM, Sutherland RM: The identification of heme oxygenase as a major hypoxic stress protein in Chinese hamster ovary cells. *Br J Cancer* 64: 69–73, 1991
123. Leach RM, Treacher DF: Clinical aspects of hypoxic pulmonary vasoconstriction. *Exp Physiol* 80: 865–875, 1995
124. Meyrick B, Reid L: Pulmonary hypertension. Anatomic and physiologic correlates. *Clin Chest Med* 4: 199–217, 1983
125. Heacock CS, Sutherland RM: Induction characteristics of oxygen regulated proteins. *Int J Radiat Oncol Biol Phys* 12: 1287–1290, 1986
126. Graven KK, Farber HW: Endothelial cell hypoxic stress proteins. *J Lab Clin Med* 132: 456–463, 1998
127. Helfman T, Falanga V: Gene expression in low oxygen tension. *Am J Med Sci* 306: 37–41, 1993
128. Zimmerman LH, Levine RA, Farber HW: Hypoxia induces a specific set of stress proteins in cultured endothelial cells. *J Clin Invest* 87: 908–914, 1991
129. Katayose D, Isoyama S, Fujita H, Shibahara S: Separate regulation of heme oxygenase and heat shock protein 70 mRNA expression in the rat heart by hemodynamic stress. *Biochem Biophys Res Commun* 191: 587–594, 1993
130. Motterlini R, Foresti R, Bassi R, Calabrese V, Clark JE, Green CJ: Endothelial heme oxygenase-1 induction by hypoxia. Modulation by inducible nitric-oxide synthase and S-nitrosothiols. *J Biol Chem* 275: 13613–13620, 2000
131. Hartsfield CL, Alam J, Choi AM: Differential signaling pathways of HO-1 gene expression in pulmonary and systemic vascular cells. *Am J Physiol* 277: L1133–L1141, 1999
132. Wood SM, Wiesener MS, Yeates KM, Okada N, Pugh CW, Maxwell PH, Ratcliffe PJ: Selection and analysis of a mutant cell line defective in the hypoxia-inducible factor-1 alpha-subunit (HIF-1alpha). Characterization of hif-1alpha-dependent and -independent hypoxia-inducible gene expression. *J Biol Chem* 273: 8360–8368, 1998
133. Freeman BA, Crapo JD: Hyperoxia increases oxygen radical production in rat lungs and lung mitochondria. *J Biol Chem* 256: 10986–10992, 1981
134. Dennery PA, Rodgers PA, Lum MA, Jennings BC, Shokoohi V: Hyperoxic regulation of lung heme oxygenase in neonatal rats. *Pediatr Res* 40: 815–821, 1996
135. Takahashi S, Takahashi Y, Yoshimi T, Miura T: Oxygen tension regulates heme oxygenase-1 gene expression in mammalian cell lines. *Cell Biochem Funct* 16: 183–193, 1998

136. Shibahara S, Muller RM, Taguchi H: Transcriptional control of rat heme oxygenase by heat shock. *J Biol Chem* 262: 12889–12892, 1987
137. Müller RM, Taguchi H, Shibahara S: 1987. Nucleotide sequence and organization of the rat heme oxygenase gene. *J Biol Chem* 262: 6795–6802
138. Ewing JF, Maines MD: Rapid induction of heme oxygenase-1 mRNA and protein by hyperthermia in rat brain: Heme oxygenase-2 is not a heat shock protein. *Proc Natl Acad Sci USA* 88: 5364–5368, 1991
139. Raju VS, Maines MD: Coordinated expression and mechanism of induction of HSP32 (heme oxygenase-1) mRNA by hyperthermia in rat organs. *Biochim Biophys Acta* 1217: 273–280, 1994
140. Ewing JF, Haber SN, Maines MD: Normal and heat-induced patterns of expression of heme oxygenase-1 (HSP32) in rat brain: Hyperthermia causes rapid induction of mRNA and protein. *J Neurochem* 58: 1140–1149, 1992
141. Ewing JF, Raju VS, Maines MD: Induction of heart heme oxygenase-1 (HSP32) by hyperthermia: Possible role in stress-mediated elevation of cyclic 3':5'-guanosine monophosphate. *J Pharmacol Exp Ther* 271: 408–414, 1994
142. Okinaga S, Shibahara S: Identification of a nuclear protein that constitutively recognizes the sequence containing a heat-shock element. Its binding properties and possible function modulating heat-shock induction of the rat heme oxygenase gene. *Eur J Biochem* 212: 167–175, 1993
143. Shibahara S, Sato M, Muller RM, Yoshida T: Structural organization of the human heme oxygenase gene and the function of its promoter. *Eur J Biochem* 179: 557–563, 1989
144. Alam J, Cai J, Smith A: Isolation and characterization of the mouse heme oxygenase-1 gene. Distal 5' sequences are required for induction by heme or heavy metals. *J Biol Chem* 269: 1001–1009, 1994
145. Okinaga S, Takahashi K, Takeda K, Yoshizawa M, Fujita H, Sasaki H, Shibahara S: Regulation of human heme oxygenase-1 gene expression under thermal stress. *Blood* 87: 5074–5084, 1996
146. Yoshida T, Biro P, Cohen T, Muller RM, Shibahara S: Human heme oxygenase cDNA and induction of its mRNA by hemin. *Eur J Biochem* 171: 457–461, 1988
147. Elbirt KK, Whitmarsh AJ, Davis RJ, Bonkovsky HL: Mechanism of sodium arsenite-mediated induction of heme oxygenase-1 in hepatoma cells. Role of mitogen-activated protein kinases. *J Biol Chem* 273: 8922–8931, 1998
148. Alam J, Wicks C, Stewart D, Gong P, Touchard C, Otterbein S, Choi AM, Burow ME, Tou J: Mechanism of heme oxygenase-1 gene activation by cadmium in MCF-7 mammary epithelial cells. Role of p38 kinase and Nrf2 transcription factor. *J Biol Chem* 275: 27694–27702, 2000
149. Masuya Y, Hioki K, Tokunaga R, Taketani S: Involvement of the tyrosine phosphorylation pathway in induction of human heme oxygenase-1 by hemin, sodium arsenite, and cadmium chloride. *J Biochem (Tokyo)* 124: 628–633, 1998
150. Kacimi R, Chentoufi J, Honbo N, Long CS, Karliner JS: Hypoxia differentially regulates stress proteins in cultured cardiomyocytes: Role of the p38 stress-activated kinase signaling cascade, and relation to cytoprotection. *Cardiovasc Res* 46: 139–150, 2000
151. Ryter S, Xi S, Choi AM: Mitogen activated protein kinase (MAPK) pathway regulates heme oxygenase-1 gene expression by hypoxia in vascular cells. *Antioxid Redox Signal*: 2002, (in press)
152. Yu R, Chen C, Mo YY, Hebbar V, Owuor ED, Tan TH, Kong AN: Activation of mitogen-activated protein kinase pathways induces antioxidant response element-mediated gene expression via a Nrf2-dependent mechanism. *J Biol Chem* 275: 39907–39913, 2000
153. Alam J, Den Z: Distal AP-1 binding sites mediate basal level enhancement and TPA induction of the mouse heme oxygenase-1 gene. *J Biol Chem* 267: 21894–21900, 1992
154. Alam J: Multiple elements within the 5' distal enhancer of the mouse heme oxygenase-1 gene mediate induction by heavy metals. *J Biol Chem* 269: 25049–25056, 1994
155. Alam J, Camhi S, Choi AM: Identification of a second region upstream of the mouse heme oxygenase-1 gene that functions as a basal level and inducer-dependent transcription enhancer. *J Biol Chem* 270: 11977–11984, 1995
156. Camhi SL, Alam J, Otterbein L, Sylvester SL, Choi AM: Induction of heme oxygenase-1 gene expression by lipopolysaccharide is mediated by AP-1 activation. *Am J Respir Cell Mol Biol* 13: 387–398, 1995
157. Alam J, Stewart D, Touchard C, Boinapally S, Choi AM, Cook JL: Nrf2, a Cap'n'collar transcription factor, regulates induction of the heme oxygenase-1 gene. *J Biol Chem* 274: 26071–26078, 1999
158. Inamdar NM, Ahn YI, Alam J: The heme-responsive element of the mouse heme oxygenase-1 gene is an extended AP-1 binding site that resembles the recognition sequences for MAF and NF-E2 transcription factors. *Biochem Biophys Res Commun* 221: 570–576, 1996
159. He CH, Gong P, Hu B, Stewart D, Choi ME, Choi AM, Alam J: Identification of activating transcription factor 4 (ATF4) as a Nrf2 interacting protein: Implication for heme oxygenase-1 gene regulation. *J Biol Chem* 276: 20858–20865, 2001
160. Lee PJ, Camhi SL, Chin BY, Alam J, Choi AM: AP-1 and STAT mediate hyperoxia-induced gene transcription of heme oxygenase-1. *Am J Physiol Lung Cell Mol Physiol* 279: L175–L182, 2000
161. Otterbein L, Sylvester SL, Choi AM: Hemoglobin provides protection against lethal endotoxemia in rats: The role of heme oxygenase-1. *Am J Respir Cell Mol Biol* 13: 595–601, 1995
162. Nath KA, Balla G, Vercellotti GM, Balla J, Jacob HS, Levitt MD, Rosenberg ME: Induction of heme oxygenase is a rapid, protective response in rhabdomyolysis in the rat. *J Clin Invest* 90: 267–270, 1992
163. Nath KA, Vercellotti GM, Grande JP, Miyoshi H, Paya CV, Manivel JC, Haggard JJ, Croatt AJ, Payne WD, Alam J: Heme protein-induced chronic renal inflammation: Suppressive effect of induced heme oxygenase-1. *Kidney Int* 59: 106–117, 2001
164. Vogt BA, Alam J, Croatt AJ, Vercellotti GM, Nath KA: Acquired resistance to acute oxidative stress. Possible role of heme oxygenase and ferritin. *Lab Invest* 72: 474–483, 1995
165. Fujita T, Toda K, Karimova A, Yan SF, Naka Y, Yet SF, Pinsky DJ: Paradoxical rescue from ischemic lung injury by inhaled carbon monoxide driven by derepression of fibrinolysis. *Nat Med* 7: 598–604, 2001
166. Duckers HJ, Boehm M, True AL, Yet SF, San H, Park JL, Webb RC, Lee ME, Nabel GJ, Nabel EG: Heme oxygenase-1 protects against vascular constriction and proliferation. *Nat Med* 7: 693–698, 2001
167. Yet SF, Perrella MA, Layne MD, Hsieh CM, Maemura K, Kobzik L, Wiesel P, Christou H, Kourembanas S, Lee ME: Hypoxia induces severe right ventricular dilatation and infarction in heme oxygenase-1 null mice. *J Clin Invest* 103: R23–R29, 1999
168. Christou H, Morita T, Hsieh CM, Koike H, Arkonac B, Perrella MA, Kourembanas S: Prevention of hypoxia-induced pulmonary hypertension by enhancement of endogenous heme oxygenase-1 in the rat. *Circ Res* 86: 1224–1229, 2000
169. Minamino T, Christou H, Hsieh CM, Liu Y, Dhawan V, Abraham NG, Perrella MA, Mitsialis SA, Kourembanas S: Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory

- and vascular responses to hypoxia. *Proc Natl Acad Sci USA* 98: 8798–8803, 2001
170. Dennery PA, Spitz DR, Yang G, Tatarov A, Lee CS, Shegog ML, Poss KD: Oxygen toxicity and iron accumulation in the lungs of mice lacking heme oxygenase-2. *J Clin Invest* 101: 1001–1011, 1998
 171. Wang LJ, Lee TS, Lee FY, Pai RC, Chau LY: Expression of heme oxygenase-1 in atherosclerotic lesions. *Am J Pathol* 152: 711–720, 1998
 172. Juan SH, Lee TS, Tseng KW, Liou JY, Shyue SK, Wu KK, Chau LY: Adenovirus-mediated heme oxygenase-1 gene transfer inhibits the development of atherosclerosis in apolipoprotein E-deficient mice. *Circulation* 104: 1519–1525, 2001
 173. Ishikawa K, Sugawara D, Wang X, Suzuki K, Itabe H, Maruyama Y, Lusis AJ: Heme oxygenase-1 inhibits atherosclerotic lesion formation in ldl-receptor knockout mice. *Circ Res* 88: 506–512, 2001
 174. Chen K, Gunter K, Maines MD: Neurons overexpressing heme oxygenase-1 resist oxidative stress-mediated cell death. *J Neurochem* 75: 304–313, 2000
 175. Kvam E, Hejmadi V, Ryter S, Pourzand C, Tyrrell RM: Heme oxygenase activity causes transient hypersensitivity to oxidative ultraviolet a radiation that depends on release of iron from heme. *Free Radic Biol Med* 28: 1191–1196, 2000
 176. Suttner DM, Dennery PA: Reversal of HO-1 related cytoprotection with increased expression is due to reactive iron. *FASEB J* 13: 1800–1809, 1999
 177. Vremen HJ, Wong RJ, Stevenson DK: Carbon monoxide in breath, blood, and other tissues. In: D.G. Penney (ed). *Carbon Monoxide Toxicity*. CRC Press, Boca Raton, FL, 2000, pp 19–60
 178. Raub JA: The setting of health-based standards for ambient carbon monoxide and their impact on atmospheric levels. In: D.G. Penney (ed). *Carbon Monoxide Toxicity*. CRC Press, Boca Raton, FL, 2000, pp 83–99
 179. Federal Trade Commission: 'Tar,' Nicotine, and Carbon Monoxide of the Smoke of 1294 Varieties of Domestic Cigarettes for the Year 1998: Federal Trade Commission Report to Congress (July 2000). Federal Trade Commission, Washington, DC
 180. Ignarro LJ: Nitric oxide-mediated vasorelaxation. *Thromb Haem* 70: 148–151, 1993
 181. Snyder SH, Bredt DS: Biological roles of nitric oxide. *Sci Am* 266: 68–71, 1992
 182. Kharitonov VG, Sharma VS, Pilz RB, Magde D, Koesling D: Basis of guanylate cyclase activation by carbon monoxide. *Proc Natl Acad Sci USA* 92: 2568–2571, 1995
 183. Stone JR, Marletta MA: Soluble guanylate cyclase from bovine lung: Activation with nitric oxide and carbon monoxide and spectral characterization of the ferrous and ferric states. *Biochemistry* 33: 5636–5640, 1994
 184. Kvam E, Noel A, Basu-Modak S, Tyrrell RM: Cyclooxygenase dependent release of heme from microsomal hemoproteins correlates with induction of heme oxygenase 1 transcription in human fibroblasts. *Free Radic Biol Med* 26: 511–517, 1999
 185. Tenhunen R, Marver H, Pimstone NR, Trager WF, Cooper DY, Schmid R: Enzymatic degradation of heme. Oxygenative cleavage requiring cytochrome P-450. *Biochemistry* 11: 1716–1720, 1972
 186. Raju VS, Maines MD: Renal ischemia/reperfusion up-regulates heme oxygenase-1 (HSP32) expression and increases cGMP in rat heart. *J Pharmacol Exp Ther* 277: 1814–1822, 1996
 187. Caudill TK, Resta TC, Kanagy NL, Walker BR: Role of endothelial carbon monoxide in attenuated vasoreactivity following chronic hypoxia. *Am J Physiol* 275: R1025–R1030, 1998
 188. Leffler CW, Nasjletti A, Yu C, Johnson RA, Fedinec AL, Walker N: Carbon monoxide and cerebral microvascular tone in newborn pigs. *Am J Physiol* 276: H1641–H1646, 1999
 189. Rattan S, Chakder S: Inhibitory effect of CO on internal anal sphincter: Heme oxygenase inhibitor inhibits NANC relaxation. *Am J Physiol* 265: G799–G804, 1993
 190. Suematsu M, Kashiwagi S, Sano T, Goda N, Shinoda Y, Ishimura Y: Carbon monoxide as an endogenous modulator of hepatic vascular perfusion. *Biochem Biophys Res Commun* 205: 1333–1337, 1994
 191. Siow RC, Sato H, Mann GE: Heme oxygenase-carbon monoxide signalling pathway in atherosclerosis: Anti-atherogenic actions of bilirubin and carbon monoxide? *Cardiovasc Res* 41: 385–394, 1999
 192. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F: Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. *J Biol Chem* 274: 10689–10692, 1999
 193. Hambleton J, Weinstein SL, Lem L, DeFranco AL: Activation of c-Jun N-terminal kinase in bacterial lipopolysaccharide-stimulated macrophages. *Proc Natl Acad Sci USA* 93: 2774–2778, 1996
 194. Han J, Lee JD, Bibbs L, Ulevitch RJ: A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. *Science* 265: 808–811, 1994
 195. Raingeaud J, Gupta S, Rogers JS, Dickens M, Han J, Ulevitch RJ, Davis RJ: Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. *J Biol Chem* 270: 7420–7426, 1995
 196. Derijard B, Raingeaud J, Barrett T, Wu IH, Han J, Ulevitch RJ, Davis RJ: Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. *Science* 267: 682–685, 1995
 197. Raingeaud J, Whitmarsh AJ, Barrett T, Derijard B, Davis RJ: MKK3 and MKK6 regulation of gene expression is mediated by the p38 MAP kinase signal transduction pathway. *Mol Cell Biol* 16: 1247–1255, 1996
 198. Brown SD, Piantadosi CA: *In vivo* binding of carbon monoxide to cytochrome c oxidase in rat brain. *J Appl Physiol* 68: 604–610, 1990
 199. Piantadosi CA, Sylvia AL, Jobsis-Vandervliet FF: Differences in brain cytochrome responses to carbon monoxide and cyanide *in vivo*. *J Appl Physiol* 62: 1277–1284, 1987
 200. Clark JM, Lambertson CJ: Pulmonary oxygen toxicity: A review. *Pharmacol Rev* 23: 37–133, 1971
 201. Thom SR, Fisher D, Xu YA, Notarfrancesco K, Ishiropoulos H: Adaptive responses and apoptosis in endothelial cells exposed to carbon monoxide. *Proc Natl Acad Sci* 97: 1305–1310, 2000
 202. Choi AM, Alam J: Heme oxygenase-1: Function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury. *Am J Respir Cell Mol Biol* 15: 9–19, 1996

